Silibinin Suppresses Growth and Induces Apoptotic Death of Human Colorectal Carcinoma LoVo Cells in Culture and Tumor Xenograft

Overview

Journal Mol Cancer Ther

Date 2009 Jul 30

PMID 19638451

Citations 42

Authors

Manjinder Kaur

Balaiya Velmurugan

Alpna Tyagi

Gagan Deep

Suchitra Katiyar

Chapla Agarwal

Rajesh Agarwal

Affiliations

Soon will be listed here.

Abstract

Colorectal cancer is one of the leading causes of cancer-related morbidity and mortality. The use of nontoxic phytochemicals in the prevention and intervention of colorectal cancer has been suggested as an alternative to chemotherapy. Here we assessed the anticancer efficacy of silibinin against advanced colorectal cancer LoVo cells both in vitro and in vivo. Our results showed that silibinin treatment strongly inhibits the growth of LoVo cells (P < 0.05-0.001) and induces apoptotic death (P < 0.01-0.001), which was associated with increased levels of cleaved caspases (3 and 9) and cleaved poly(ADP-ribose) polymerase. Additionally, silibinin caused a strong cell cycle arrest at G(1) phase and a slight but significant G(2)-M-phase arrest at highest concentration (P < 0.01-0.001). Molecular analyses for cell cycle regulators showed that silibinin decreases the level of cyclins (D1, D3, A and B1) and cyclin-dependent kinases (1, 2, 4, and 6) and increases the level of cyclin-dependent kinase inhibitors (p21 and p27). Consistent with these results, silibinin treatment also decreased the phosphorylation of retinoblastoma protein at Ser(780), Ser(795), and Ser(807)/Ser(811) sites without significantly affecting its total level. In animal studies, oral administration of silibinin for 6 weeks (at 100 and 200 mg/kg/d for 5 days/wk) significantly inhibited the growth of LoVo xenograft (P < 0.001) in athymic nude mice without any apparent toxicity. Analyses of xenograft tissue showed that silibinin treatment inhibits proliferation and increases apoptosis along with a strong increase in p27 levels but a decrease in retinoblastoma phosphorylation. Together, these results suggest the potential use of silibinin against advanced human colorectal cancer.

Citing Articles

Targeted delivery of silibinin via magnetic niosomal nanoparticles: potential application in treatment of colon cancer cells.

Shafiei G, Jafari-Gharabaghlou D, Farhoudi-Sefidan-Jadid M, Alizadeh E, Fathi M, Zarghami N Front Pharmacol. 2023; 14:1174120.

PMID: 37441534 PMC: 10335571. DOI: 10.3389/fphar.2023.1174120.

Silibinin exhibits anti-tumor effects in a breast cancer stem cell model by targeting stemness and induction of differentiation and apoptosis.

Firouzi J, Sotoodehnejadnematalahi F, Shokouhifar A, Rahimi M, Sodeifi N, Sahranavardfar P Bioimpacts. 2022; 12(5):415-429.

PMID: 36381630 PMC: 9596878. DOI: 10.34172/bi.2022.23336.

Synergistic antitumor effects of polysaccharides and anthocyanins from Murr. on human colorectal carcinoma LoVo cells and the molecular mechanism.

Qin X, Wang X, Xu K, Yang X, Wang Q, Liu C Food Sci Nutr. 2022; 10(9):2956-2968.

PMID: 36171788 PMC: 9469862. DOI: 10.1002/fsn3.2892.

Silymarin (milk thistle extract) as a therapeutic agent in gastrointestinal cancer.

Fallah M, Davoodvandi A, Nikmanzar S, Aghili S, Mirazimi S, Aschner M Biomed Pharmacother. 2021; 142:112024.

PMID: 34399200 PMC: 8458260. DOI: 10.1016/j.biopha.2021.112024.

Targeting the hallmarks of cancer: the effects of silibinin on proliferation, cell death, angiogenesis, and migration in colorectal cancer.

Sameri S, Mohammadi C, Mehrabani M, Najafi R BMC Complement Med Ther. 2021; 21(1):160.

PMID: 34059044 PMC: 8168007. DOI: 10.1186/s12906-021-03330-1.

References

Deep G, Agarwal R . New combination therapies with cell-cycle agents. Curr Opin Investig Drugs. 2008; 9(6):591-604. PMC: 2440501. View

Rubin S, Gall A, Zheng N, Pavletich N . Structure of the Rb C-terminal domain bound to E2F1-DP1: a mechanism for phosphorylation-induced E2F release. Cell. 2005; 123(6):1093-106. DOI: 10.1016/j.cell.2005.09.044. View

Porter P, Malone K, Heagerty P, Alexander G, Gatti L, Firpo E . Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med. 1997; 3(2):222-5. DOI: 10.1038/nm0297-222. View

Luper S . A review of plants used in the treatment of liver disease: part 1. Altern Med Rev. 1998; 3(6):410-21. View

Kohno H, Tanaka T, Kawabata K, Hirose Y, Sugie S, Tsuda H . Silymarin, a naturally occurring polyphenolic antioxidant flavonoid, inhibits azoxymethane-induced colon carcinogenesis in male F344 rats. Int J Cancer. 2002; 101(5):461-8. DOI: 10.1002/ijc.10625. View

Hanahan D, Weinberg R . The hallmarks of cancer. Cell. 2000; 100(1):57-70. DOI: 10.1016/s0092-8674(00)81683-9. View

Ziegler D, Kung A . Therapeutic targeting of apoptosis pathways in cancer. Curr Opin Oncol. 2007; 20(1):97-103. DOI: 10.1097/CCO.0b013e3282f310f6. View

Loda M, Cukor B, Tam S, Lavin P, Fiorentino M, Draetta G . Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med. 1997; 3(2):231-4. DOI: 10.1038/nm0297-231. View

Nickeleit I, Zender S, Kossatz U, Malek N . p27kip1: a target for tumor therapies?. Cell Div. 2007; 2:13. PMC: 1872022. DOI: 10.1186/1747-1028-2-13. View

10.

Kidd P, Head K . A review of the bioavailability and clinical efficacy of milk thistle phytosome: a silybin-phosphatidylcholine complex (Siliphos). Altern Med Rev. 2005; 10(3):193-203. View

11.

Agarwal C, Singh R, Dhanalakshmi S, Tyagi A, Tecklenburg M, Sclafani R . Silibinin upregulates the expression of cyclin-dependent kinase inhibitors and causes cell cycle arrest and apoptosis in human colon carcinoma HT-29 cells. Oncogene. 2003; 22(51):8271-82. DOI: 10.1038/sj.onc.1207158. View

12.

Hogan F, Krishnegowda N, Mikhailova M, Kahlenberg M . Flavonoid, silibinin, inhibits proliferation and promotes cell-cycle arrest of human colon cancer. J Surg Res. 2007; 143(1):58-65. DOI: 10.1016/j.jss.2007.03.080. View

13.

Nakayama K, Nakayama K . Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer. 2006; 6(5):369-81. DOI: 10.1038/nrc1881. View

14.

Gescher A . Polyphenolic phytochemicals versus non-steroidal anti-inflammatory drugs: which are better cancer chemopreventive agents?. J Chemother. 2005; 16 Suppl 4:3-6. DOI: 10.1179/joc.2004.16.Supplement-1.3. View

15.

McLoughlin P, Roengvoraphoj M, Gissel C, Hescheler J, Certa U, Sachinidis A . Transcriptional responses to epigallocatechin-3 gallate in HT 29 colon carcinoma spheroids. Genes Cells. 2004; 9(7):661-9. DOI: 10.1111/j.1356-9597.2004.00754.x. View

16.

Millikan K, Staren E, Doolas A . Invasive therapy of metastatic colorectal cancer to the liver. Surg Clin North Am. 1997; 77(1):27-48. DOI: 10.1016/s0039-6109(05)70531-4. View

17.

Logue S, Martin S . Caspase activation cascades in apoptosis. Biochem Soc Trans. 2008; 36(Pt 1):1-9. DOI: 10.1042/BST0360001. View

18.

Murray A . Recycling the cell cycle: cyclins revisited. Cell. 2004; 116(2):221-34. DOI: 10.1016/s0092-8674(03)01080-8. View

19.

Tyagi A, Agarwal C, Agarwal R . The cancer preventive flavonoid silibinin causes hypophosphorylation of Rb/p107 and Rb2/p130 via modulation of cell cycle regulators in human prostate carcinoma DU145 cells. Cell Cycle. 2002; 1(2):137-42. View

20.

Ladas E, Kelly K . Milk thistle: is there a role for its use as an adjunct therapy in patients with cancer?. J Altern Complement Med. 2003; 9(3):411-6. DOI: 10.1089/107555303765551633. View